MedTrace Logo

MPOD in Macular Teleangiectasia Following Supplementation of Lutein and Zeaxanthin

NCT00568828 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2007-12-06

No results posted yet for this study

Summary

Earlier investigations have detected low levels of macular pigment (MP) in the center of the fovea and a halo of MP at a higher eccentricity in persons with type 2 idiopathic juxtafoveal teleangiectasia (MACTEL)\[Helb H-M, Charbel Issa P, Pauleikhoff D, Scholl HPN, Holz FG, MacTel-Study Group. Macular Pigment Density and Distribution in Patients with Macular Telangiectasia. ARVO Annual Meeting 2006, Fort Lauderdale, 30.04.-5.05.2006. Program # 5701/B795\]. To date it is not known whether the total MP is reduced in MACTEL or whether even more MP accumulates at higher eccenticities compared to healthy probands. With the suggested study we aim to

1. investigate Lutein and Zeaxanthin serum levels in MACTEL probands
2. investigate and quantify MP at the posterior pole of MACTEL probands
3. detect possible changes of MP concentration and distribution following supplementation with Lutein and Zeaxanthin

Conditions

  • Macular Teleangiectasia
  • Macular Pigment

Sponsors & Collaborators

  • The Lowy Medical Research Institute Limited

    lead OTHER

Principal Investigators

  • Daniel Pauleikhoff, MD · Chairman Dep. of Ophthalmology, St.Franziskus Hospital, Muenster, Germany

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Completion
2008-02-29

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00568828 on ClinicalTrials.gov